NIH-supported trials to test synthetic antibody treatments
Researchers have launched two clinical trials to test whether monoclonal (laboratory-made) antibodies can safely prevent SARS-CoV-2 infection or symptoms in healthy adults, the National Institutes of Health announced yesterday.
One trial will evaluate a Regeneron Pharmaceuticals investigational treatment in about 2,000 asymptomatic adults who are household contacts of people infected with SARS-CoV-2.
The other will assess an Eli Lilly and Company investigational treatment in up to 2,400 people who reside or work in skilled nursing or assisted living facilities.
Related News Articles
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…